[ad_1]
FILE PHOTO: The logo of the pharmaceutical company AstraZeneca is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, USA, April 8, 2019. REUTERS / Brendan McDermid / File Photo
AstraZeneca Plc said Monday that it began enrolling 30,000 participants over the age of 18 in a late-stage study to evaluate its COVID-19 vaccine candidate, AZD1222.
Participants are being randomly assigned to receive either two doses of AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine as the saline control, the company said.
The study is being funded by the US government, the London-listed company said.
For more news on the new coronavirus, click here.
What you need to know about the coronavirus.
For more information on COVID-19, call the DOH hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our leaders in healthcare and still accepts cash donations to be deposited into the Banco de Oro (BDO) checking account # 007960018860 or donate through PayMaya using this link .
Read next
EDITOR’S SELECTION
MOST READ
Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer and more than 70 other titles, share up to 5 gadgets, listen to the news, download from 4am and share articles on social media. Call 896 6000.
For comments, complaints or inquiries, please contact us.
[ad_2]
